IREN proposes $875 million convertible notes offering due 2031
Investing.com - TD Cowen has reiterated its Buy rating on Roivant Sciences (NASDAQ:ROIV), currently trading at $13.71 and near its 52-week high, following a favorable court ruling in a patent dispute between Arbutus Biopharma and Pfizer/BioNTech. InvestingPro data shows analyst targets reaching as high as $22.
The court sided with Arbutus Biopharma on three of four claims in a construction order against Pfizer and BioNTech involving five patents related to lipid nanoparticle (LNP) composition and production methods.
TD Cowen analyst Yaron Werber noted that the judge reversed previous mRNA precedence to side with Arbutus on composition patents, which represents a significant development in the ongoing intellectual property litigation.
The judge partially sided with Pfizer on the definition of "consisting essentially of" in the ’378 patent, which was the only claim not fully favorable to Arbutus.
TD Cowen expressed encouragement about the ruling, particularly highlighting the importance of the molar ratio patents to Arbutus’s case against the vaccine manufacturers.
In other recent news, Roivant Sciences reported its Q1 2026 earnings, revealing a greater-than-expected loss and a significant revenue shortfall. The company posted an EPS of -$0.33, falling short of the forecasted -$0.25, and reported revenue of $2.17 million, significantly below the anticipated $7.69 million. Meanwhile, TD Cowen has reiterated its Buy rating on Roivant Sciences, maintaining its positive stance ahead of key clinical data expected in September 2025. This data pertains to the Phase 3 VALOR DM trial results for brepocitinib, an oral JAK1/TYK2 inhibitor being evaluated for dermatomyositis. In related developments, Japan’s Ministry of Health, Labour and Welfare granted orphan drug designation to mosliciguat, Pulmovant’s experimental treatment for pulmonary hypertension associated with interstitial lung disease (PH-ILD). This designation provides Pulmovant with regulatory benefits, including priority consultation, reduced fees, and up to 10 years of market exclusivity if approved. These recent developments highlight significant regulatory and financial activities within the biopharmaceutical sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.